Tagrisso from AstraZeneca plc - early lung cancer use reshapes the label

Reviewed: ad hoc news New Release & Launch desk. Edited and checked on 2026-06-23, 06:45. Details in the imprint.

Tagrisso from AstraZeneca plc is one of those quiet hospital drugs that changes the tone of a consultation. The oncologist explains that a pill taken at home after surgery could significantly cut the risk of lung cancer coming back. The chemo chair, the beeping drip stand, suddenly feel less permanent.

What Tagrisso is targeting

Tagrisso, generic name osimertinib, is a targeted therapy for EGFR-mutated non-small cell lung cancer, the most common lung cancer type. It is an oral tablet that blocks aberrant EGFR signalling, including the resistance T790M mutation. Patients usually take it once daily with or without food.

In its original role, Tagrisso mainly served patients whose tumors had already developed resistance to earlier EGFR inhibitors. They often arrived after months of scans and clinical setbacks. Today, the drug is moving earlier in the treatment journey, into the adjuvant setting after surgery for localized disease.

The adjuvant approval shift

The big change for Tagrisso is its use after complete surgical resection of early-stage EGFR-mutated lung cancer, known as adjuvant therapy. In the phase 3 ADAURA trial, three years of Tagrisso cut the risk of disease recurrence or death by around 80 percent versus placebo.

Regulators have moved fast on these data. The US Food and Drug Administration and other agencies have expanded Tagrisso's label to include adjuvant treatment in certain stages, reshaping standard of care for this molecularly defined subgroup. For patients and doctors, that means more consultations end with a prescription rather than a watch-and-wait plan.

Daily use and side effects

In everyday practice, Tagrisso comes as film-coated tablets, commonly 80 mg once daily. Patients swallow them with a glass of water at the kitchen table, a small routine that quietly anchors their follow-up care. The packaging is compact and clearly labelled, designed for home use.

Side effects are manageable for many but not trivial. Common issues include diarrhea, rash, and nail changes, along with more serious risks like interstitial lung disease and heart rhythm changes. Oncologists such as Dave Fredrickson, AstraZeneca's Executive Vice-President, Oncology Business Unit, frequently stress the need for careful monitoring when the drug is used for years in otherwise asymptomatic patients.

Pricing and market reach

Tagrisso is a high-value oncology therapy, priced at a premium typical for targeted cancer medicines. In major markets like the US and EU, it is reimbursed largely through public or private payers after health-technology assessments. Patients rarely see the full list price but may face co-pays depending on insurance.

The drug is available across oncology centers worldwide, including Europe, North America and key Asian markets. Access still varies by country, guideline adoption and molecular testing infrastructure. Without routine EGFR testing on surgical samples, the adjuvant indication remains theoretical rather than practical.

Where Tagrisso fits for investors

For AstraZeneca, Tagrisso sits at the core of the oncology portfolio alongside other targeted and immuno-oncology assets. It has already reached multi-billion-dollar annual sales and the adjuvant indication is expected to extend its lifecycle. Net-net, the drug is a central pillar of the company's growth story.

AstraZeneca shares (ISIN GB0009895292) trade primarily on the London Stock Exchange, with additional listings as ADRs in New York, giving investors broad access to the company's oncology-driven revenues.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.